Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 849

A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 835

A Meta-Analysis to Determine If the Prevalence of Scleroderma Renal Crisis Decreasing with Time

9:00AM-11:00AM: Abstract Number: 823

Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene

9:00AM-11:00AM: Abstract Number: 822

Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial

9:00AM-11:00AM: Abstract Number: 830

Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 842

Clinical Utility of Serial KL-6 Measurement in Interstitial Lung Disease Associated with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 828

Development of a Disease Damage Index in Systemic Sclerosis Using Consensus and Data Driven Methods

9:00AM-11:00AM: Abstract Number: 851

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?

9:00AM-11:00AM: Abstract Number: 821

Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 837

Exposure to ACE Inhibitors Prior to Onset of Scleroderma Renal Crisis Is Not Associated with Increased Risk of Mortality in a Large Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 824

Familial Risk of Systemic Sclerosis and Co-Aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study

9:00AM-11:00AM: Abstract Number: 829

Fecal Incontinence and Association with Bowel Dysfunction in Systemic Sclerosis: A Canadian Multicenter Study

9:00AM-11:00AM: Abstract Number: 852

Health-Related Quality of Life in Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 844

Identification of Subclinical Skin Involvement By High Frequency Ultrasound in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 838

Impaired Quality of Life in Systemic Sclerosis and Patient Perception of the Disease: A Large International Survey

9:00AM-11:00AM: Abstract Number: 850

Incidence and Predictors of Severe Heart Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 836

Influence of B Cell Depletion By Monoclonal Anti CD20 Antibodies in Systemic Sclerosis: Results of a Randomized Placebo Controlled Trial

9:00AM-11:00AM: Abstract Number: 845

Modelling of Longitudinal Changes in Lung Function in Patients with Systemic Sclerosis and Their Association with Development of Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 831

Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 846

Nationwide Trends in in-Hospital Mortality and Hospitalization Associated with Systemic Sclerosis (SSc)

9:00AM-11:00AM: Abstract Number: 843

Natriuretic Peptide Predicts Mortality in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 848

Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging

9:00AM-11:00AM: Abstract Number: 839

Occupational Exposures in Patients with Systemic Sclerosis Associated with Increased Frequency of Interstitial Lung Disease and Primary Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 841

Prevalence of Systemic Sclerosis in Primary Biliary Cirrhosis Using the New ACR/EULAR Classification Criteria

9:00AM-11:00AM: Abstract Number: 827

Reliability of the Quantitative Assessment of Peripheral Blood Perfusion By Laser Speckle Contrast Analysis in a Systemic Sclerosis Cohort

9:00AM-11:00AM: Abstract Number: 833

Safety and Immunogenicity of Pneumococcal Vaccine in Patients with Systemic Sclerosis and Healthy Controls

9:00AM-11:00AM: Abstract Number: 840

Skin Telangiectasia Identify a Subset of Systemic Sclerosis Patients with Severe Vascular Phenotype

9:00AM-11:00AM: Abstract Number: 825

Subclinical Atherosclerosis and Estimation of Cardiovascular Risk in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 826

Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.

9:00AM-11:00AM: Abstract Number: 834

The Efficacy of Rituximab in Systemic Sclerosis Joint Disease: A Pilot Study

9:00AM-11:00AM: Abstract Number: 832

The Validity and Reliability of Online Obituaries As a Source of Mortality Data

9:00AM-11:00AM: Abstract Number: 847

Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].